AR inhibition remains the mainstay treatment for metastatic prostate cancer, a practice grounded in seminal experiments from 1941, which demonstrated the androgen-driven and androgen-dependent nature of prostate cancer [37]. Here, AR is linked to metastatic prostate carcinoma.